Literature DB >> 31730795

Behavioral Evaluation of Angelman Syndrome Mice at Older Ages.

Rebecca Dutta1, Jacqueline N Crawley2.   

Abstract

Angelman syndrome is a neurodevelopmental disorder presenting with severe deficits in motor, speech, and cognitive abilities. The primary genetic cause of Angelman syndrome is a maternally transmitted mutation in the Ube3a gene, which has been successfully modeled in Ube3a mutant mice. Phenotypes have been extensively reported in young adult Ube3a mice. Because symptoms continue throughout life in Angelman syndrome, we tested multiple behavioral phenotypes of male Ube3a mice and WT littermate controls at older adult ages. Social behaviors on both the 3-chambered social approach and male-female social interaction tests showed impairments in Ube3a at 12 months of age. Anxiety-related scores on both the elevated plus-maze and the light ↔ dark transitions assays indicated anxiety-like phenotypes in 12 month old Ube3a mice. Open field locomotion parameters were consistently lower at 12 months. Reduced general exploratory locomotion at this age prevented the interpretation of an anxiety-like phenotype, and likely impacted social tasks. Robust phenotypes in middle-aged Ube3a mice appear to result from continued motor decline. Motor deficits may provide the best outcome measures for preclinical testing of pharmacological targets, towards reductions of symptoms in adults with Angelman syndrome.
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  12 month old; Angelman; Ube3a mice; anxiety-related; exploration; social behavior

Mesh:

Substances:

Year:  2019        PMID: 31730795      PMCID: PMC7214203          DOI: 10.1016/j.neuroscience.2019.10.027

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  67 in total

1.  Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation.

Authors:  Geeske M van Woerden; Karen D Harris; Mohammad Reza Hojjati; Richard M Gustin; Shenfeng Qiu; Rogerio de Avila Freire; Yong-hui Jiang; Ype Elgersma; Edwin J Weeber
Journal:  Nat Neurosci       Date:  2007-01-28       Impact factor: 24.884

2.  Reversal of reduced parvalbumin neurons in hippocampus and amygdala of Angelman syndrome model mice by chronic treatment of fluoxetine.

Authors:  Swetha K Godavarthi; Ankit Sharma; Nihar Ranjan Jana
Journal:  J Neurochem       Date:  2014-04-25       Impact factor: 5.372

3.  Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.

Authors:  Sara Silva-Santos; Geeske M van Woerden; Caroline F Bruinsma; Edwin Mientjes; Mehrnoush Aghadavoud Jolfaei; Ben Distel; Steven A Kushner; Ype Elgersma
Journal:  J Clin Invest       Date:  2015-04-13       Impact factor: 14.808

Review 4.  Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes.

Authors:  Angela M Mabb; Matthew C Judson; Mark J Zylka; Benjamin D Philpot
Journal:  Trends Neurosci       Date:  2011-05-17       Impact factor: 13.837

5.  Angelman and Prader-Willi syndromes share a common chromosome 15 deletion but differ in parental origin of the deletion.

Authors:  J H Knoll; R D Nicholls; R E Magenis; J M Graham; M Lalande; S A Latt
Journal:  Am J Med Genet       Date:  1989-02

6.  Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a.

Authors:  Linyan Meng; Richard E Person; Arthur L Beaudet
Journal:  Hum Mol Genet       Date:  2012-04-05       Impact factor: 6.150

7.  Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-deficient mice.

Authors:  Kiyonori Miura; Tatsuya Kishino; En Li; Hayley Webber; Pieter Dikkes; Gregory L Holmes; Joseph Wagstaff
Journal:  Neurobiol Dis       Date:  2002-03       Impact factor: 5.996

Review 8.  Genomic imprinting and uniparental disomy in Angelman and Prader-Willi syndromes: a review.

Authors:  R D Nicholls
Journal:  Am J Med Genet       Date:  1993-04-01

9.  R-loop formation at Snord116 mediates topotecan inhibition of Ube3a-antisense and allele-specific chromatin decondensation.

Authors:  Weston T Powell; Rochelle L Coulson; Michael L Gonzales; Florence K Crary; Spencer S Wong; Sarrita Adams; Robert A Ach; Peter Tsang; Nazumi Alice Yamada; Dag H Yasui; Frédéric Chédin; Janine M LaSalle
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

10.  Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.

Authors:  Imran Jamal; Vipendra Kumar; Naman Vatsa; Shashi Shekhar; Brijesh Kumar Singh; Ankit Sharma; Nihar Ranjan Jana
Journal:  Neurobiol Dis       Date:  2017-05-30       Impact factor: 5.996

View more
  5 in total

1.  Aberrant aggressive behavior in a mouse model of Angelman syndrome.

Authors:  Lilach Simchi; Hanoch Kaphzan
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

2.  Motor Deficits Coupled to Cerebellar and Striatal Alterations in Ube3am-/p+ Mice Modelling Angelman Syndrome Are Attenuated by Adenosine A2A Receptor Blockade.

Authors:  Ana Moreira-de-Sá; Francisco Q Gonçalves; João P Lopes; Henrique B Silva; Ângelo R Tomé; Rodrigo A Cunha; Paula M Canas
Journal:  Mol Neurobiol       Date:  2021-01-19       Impact factor: 5.590

3.  Sex-dependent influence of postweaning environmental enrichment in Angelman syndrome model mice.

Authors:  Jameson A Cosgrove; Lauren K Kelly; Elizabeth A Kiffmeyer; Alexander D Kloth
Journal:  Brain Behav       Date:  2022-01-04       Impact factor: 2.708

4.  Deleting a UBE3A substrate rescues impaired hippocampal physiology and learning in Angelman syndrome mice.

Authors:  Gabrielle L Sell; Wendy Xin; Emily K Cook; Mark A Zbinden; Thomas B Schaffer; Robert N O'Meally; Robert N Cole; Seth S Margolis
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

5.  Dual-isoform hUBE3A gene transfer improves behavioral and seizure outcomes in Angelman syndrome model mice.

Authors:  Matthew C Judson; Charles Shyng; Jeremy M Simon; Courtney R Davis; A Mattijs Punt; Mirabel T Salmon; Noah W Miller; Kimberly D Ritola; Ype Elgersma; David G Amaral; Steven J Gray; Benjamin D Philpot
Journal:  JCI Insight       Date:  2021-10-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.